Binnopharm Group Strengthens Scientific Base: Results of 2024 Post-Marketing Studies Presented at International Congresses
In 2024, Binnopharm Group continued to actively conduct post-marketing studies of drugs from its own portfolio in the key therapeutic areas, such as acute respiratory diseases, gastroenterology, phlebology, and proctology. Nearly 4,000 patients enrolled in the studies last year.
In addition, for the first time, the results of four post-marketing studies initiated by Binnopharm Group were presented at leading international congresses.
Two studies were presented at the United European Gastroenterology Week (UEGW, Vienna, Austria), namely, «Effect of Treatment with Urdoxa® (UDCA) as Part of Combination Therapy on the Symptoms and Quality of Life in Patients with Early Stages of Cholelithiasis» and «Efficacy and Safety of Ursodeoxycholic Acid in Prevention and Treatment of COVID-19-Associated Liver Damage on Favipiravir Therapy».
The results of the studies included, inter alia, the noted high safety of Urdoxa®, a confirmed significant improvement in the physical and psychological indicators of the quality of life in patients; rapid recovery of liver function, reduction in hospitalisation time, as well as restoration of liver size and bile outflow while taking the drug were also noted.
At the 25th Congress of the Asian Society of Vascular Surgeons (ASVS 2024, Bangkok, Thailand), Binnopharm Group presented data from the study titled “Effect of Taking VENARUS® on the Level of Venous Wall Remodelling Markers in Patients with Lower Extremity Varicose Vein Disease”. A decrease in the level of vein wall remodelling markers was observed in patients taking VENARUS® for six months. The therapy also contributed to the regression of symptoms and improvement in the patients’ quality of life.
At the 6th European Congress on Infectious Diseases in Amsterdam (The Netherlands), the ARMAN study of Kagocel®, which is under the management of Binnopharm Group, was presented. The results of the project confirmed that the interferon protection system represents a universal drug therapy aimed at treating acute respiratory viral infections and influenza in the majority of patients. This is particularly relevant for routine clinical practice where identification of the disease precursor is often impossible.
«Several years ago, Binnopharm Group set a course for strengthening its position in the field of evidence-based medicine through active participation in international scientific events and presenting research results that confirm the effectiveness and safety of the company’s products. A scientific base built on modern clinical data plays a key role for physicians, providing them with reliable information for making informed decisions when choosing the therapy. An increase in the number of studies pertaining to drugs that are already on the market helps improve the quality of medical care, introduce new therapeutic solutions and strengthen trust in the company’s products», says Natalia Oliferuk, Head of Medical Department, Binnopharm Group.
